Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. 
Via Benzinga
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
Short-acting psychedelics biotech Small Pharma Inc. 
Via Benzinga
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
Exposures Product Safety
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. 
Via Benzinga
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
From Small Pharma Inc.
Via GlobeNewswire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. 
Via Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Exposures Interest Rates
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... 
Via Benzinga
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... 
Via Benzinga
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... 
Via Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o 
Via Benzinga
Cybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.